Xcout Intel
Caspian Therapeutics, Inc.
Caspian Therapeutics is a biopharmaceutical company developing menin inhibitors, such as its lead candidate KO-7246, as potential treatments for diabetes and other chronic metabolic diseases. The company focuses on a disease-modifying approach designed to restore the body's insulin-producing capacity through the expansion and enhanced function of pancreatic beta cells.
Subscribe to see Caspian Therapeutics, Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Caspian Therapeutics, Inc. at a glance
Caspian Therapeutics, Inc. is a biotechnology company headquartered in United States. Its most recent funding round, Series A, raised $50M in September 2026. Xcout tracks 3 named people at Caspian Therapeutics, Inc., including Robert H. Spencer (Executive Officer).
Caspian Therapeutics, Inc. leadership
- Robert H. SpencerExecutive Officer
- Spike LoyDirector
- Troy E. WilsonDirector
Caspian Therapeutics, Inc. funding rounds
Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Series A | $50M | — |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Caspian Therapeutics, Inc. competitors
A few of Caspian Therapeutics, Inc.'s closest competitors — see the full list of competitors and alternatives →
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s first commercial product, KOMZIFTI (ziftomenib), a potent, selective, reversible and oral small molecule menin inhibitor; Darlifarnib, a Phase 1 first-in-human FIT-001 trial which includes multiple cohorts to evaluate darlifarnib in combination with other targeted therapies in large solid tumor indications; and KO-7246, a next-generation menin inhibitor, for use in diabetes and cardiometabolic disorders and additional next-generation menin inhibitors for use in combination with other therapies in solid tumors. The company is headquartered in San Diego, California.
Biomea Fusion, Inc. is a biopharmaceutical firm dedicated to discovering and developing innovative covalent small molecule therapies. These treatments are specifically designed for individuals suffering from genetically defined cancers and various metabolic ailments. The company's primary drug candidate, BMF-219, is a potent and selective covalent inhibitor of menin, engineered for oral administration. Menin plays a crucial role as a transcriptional regulator in the abnormal signaling pathways found across numerous cancer types. Established in 2017, Biomea Fusion's operations are headquartered in Redwood City, California.
Endsulin, Inc. is a biotechnology company developing a liver-directed gene therapy for Type 1 Diabetes. Its proprietary technology aims to re-engineer liver cells to restore the body's natural ability to produce and regulate insulin, eliminating the need for artificial insulin delivery methods.
Metabolic Solutions Development Company is a private biotechnology and drug discovery company founded in 2006. The firm focuses on investigating novel molecular targets and developing therapeutics to treat diabetes, metabolic syndrome, and related conditions.
Cambrian BioPharma, Inc. is a biotechnology company headquartered in New York, United States, focused on developing therapeutics to extend human healthspan.
Aspect Biosystems develops bioengineered cellular medicines and implantable tissue therapeutics using a proprietary bioprinting platform that integrates AI, computational design, and advanced biomaterials. The company serves the biotechnology and pharmaceutical industries by creating treatments to replace, repair, or supplement biological functions for metabolic and endocrine diseases.
Get Caspian Therapeutics, Inc.'s news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on Caspian Therapeutics, Inc. in Xcout Intel
- 3 named people with titles, LinkedIn and board committees
- 1 funding round with the investors in each, and who they co-invest with
- The full competitor set, tracking, exports and API access